Home
Live Updates
Nivolumab Plus Chemotherapy vs Chemotherapy as First-Line Treatment for Advanced Gastric Cancer/Gastroesophageal Junction Cancer/Esophageal Adenocarcinoma: 4-Year Follow-Up of the CheckMate 649 Study : comparemela.com
Nivolumab Plus Chemotherapy vs Chemotherapy as First-Line Treatment for Advanced Gastric Cancer/Gastroesophageal Junction Cancer/Esophageal Adenocarcinoma: 4-Year Follow-Up of the CheckMate 649 Study
Yelena Y. Janjigian, MD, presents 4-year follow-up data from the CheckMate 649 study investigating frontline nivolumab plus chemotherapy in patients with advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma.
Related Keywords
San Francisco ,
California ,
United States ,
Yelenay Janjigian ,
,
First Line Treatment ,
Advanced Gastric ,
Gastroesophageal Junction ,
Esophageal Adenocarcinoma ,
Year Follow Up ,
Partnership With ,
Cancers Symposium ,
Gastric Cancer ,
Gastrointestinal Cancer ,
Advanced Gastric Cancer ,
Gastroesophageal Junction Cancer ,
Checkmate 649 ,
Ge Junction Cancer ,
Nivolumab ,
Chemotherapy ,
Pd L1 ,
comparemela.com © 2020. All Rights Reserved.